Coya Therapeutics Secures $10 Million Financing To Advance Clinical And Pre-Clinical Pipeline Of Regulatory T Cell Therapeutics

Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing multiple first-in-class and best-in-class approaches that enhance regulatory T cell (Treg) function, today announced that it has raised approximately $10.3 million from institutional and accredited investors. The financing brings the total funding to date to over $20 million.